AYOXXA Biosystems GmbH, a start-up company based in Cologne (Germany) and Singapore, has developed a novel technology for multiplexed protein analysis. Its business model might be compared with iTunes. Similar to a mobile device like the iPhone, AYOXXA’s biochips can be fitted with a broad range of bioassays applications. The chip will include biomarker content provided by AYOXXA as well as novel antibody panels from development partners. Core of its patented innovation are the so called “in-situ encoded bead arrays” (IEBA). They enable the measurement of a large number of different proteins and biomolecular analytes with high accuracy using very low sample volumes. This technology will benefit many disciplines including biomedical research and pharmacological screening. To date, AYOXXA has already received numerous Awards.
First four companies selected to participate in the German Accelerator Life Sciences program in Cambridge
HTGF portfolio company AYOXXA BIOSYSTEMS Extends Series B
HTGF portfolio company AYOXXA Biosystems wins new investors to close a € 9,0m Series B round
AyoxxA Biosystems Closes Series A Financing Round